Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Although clinical remission (CR) of severe asthma has been extensively investigated, CR of mild-to-moderate asthma remains unexplored.
Objective: This study aimed to determine CR rates, contributing factors, and stability in patients with mild-to-moderate asthma.
Methods: We retrospectively analyzed 263 patients with asthma. Three-component CR was defined as no exacerbation, no daily oral corticosteroid receipt, and an Asthma Control Test score equivalent to that of the well control; 4-component CR included these parameters plus forced expiratory volume in 1 second of ≥80% predicted. CR during the 1 year and stability of CR over 10 years were retrospectively analyzed in patients with mild-to-moderate and severe asthma.
Results: The CR rates were significantly higher (4-component, 73.2%; 3-component, 81.0%) in patients with mild-to-moderate asthma compared with the CR rate in patients with severe asthma (4-component, 33.9%; and 3-component, 30.6%). A lower smoking index contributed to 3- and 4-component CR. Lower body mass index contributed to 3-component remission, and later onset and shorter asthma duration contributed to 4-component remission. In patients experiencing 4-component remission 10 years before, 80.3% maintained disease in remission; 89.1% of patients experiencing 3-component remission maintained disease in remission. In patients with disease that did not maintain 4-component CR after 10 years, predicted forced expiratory volume decreased, but no differences in inhaled corticosteroid and long-acting β-agonists/long-acting muscarinic antagonists receipt were detected between 10 years ago and the present. The current muscarinic antagonist receipt remained low, at 16.7%.
Conclusion: CR, including normalized forced expiratory volume, is obtainable and sustainable in most Japanese patients with mild-to-moderate asthma. Assessing CR in these patients may help avoid undertreatment and reduce future risks.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909757 | PMC |
| http://dx.doi.org/10.1016/j.jacig.2025.100431 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trials.
Br J Dermatol
August 2025
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA.
Background: Patients with moderate-to-severe atopic dermatitis (AD) require long-term management, and understanding the long-term safety of new treatments is a top priority for patients and healthcare professionals.
Objectives: To evaluate the safety of tralokinumab in adults and adolescents with moderate-to-severe AD by conducting an integrated safety analysis of 7 placebo-controlled trials and the ongoing, open-label extension study ECZTEND.
Methods: An initial 16-week placebo-controlled (PBO-CTRL) safety set and an all-tralokinumab (ALL-TRALO) safety set combining the placebo-controlled trials and ECZTEND (data cut-off 30 April, 2022) were analyzed.
[Emergency diagnosis and treatment of bronchial asthma].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
May 2025
Department of Emergency Medicine, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China.
Bronchial asthma is a kind of heterogeneous respiratory disease, and its emergency diagnosis and treatment face multiple challenges. This article, based on the evolution of domestic and international guidelines and consensus, explores the current confusions and shortcomings in the emergency treatment of asthma, considering the clinical specifics of emergency medicine. Due to the limited applicability of classifications such as "refractory asthma" and "severe asthma" in emergency settings, as well as the complex diagnostic process that makes clinical operations difficult, it is proposed to unify the diagnostic terminology as "acute exacerbation of bronchial asthma" (mild, moderate, severe, critical severe) in emergency work.
View Article and Find Full Text PDFAttitudes, barriers, and facilitators for the use of rescue therapy in patients with mild to moderate asthma.
J Asthma
August 2025
Pontificia Universidad Javeriana, Dental Research Center (CIO), Bogotá, Colombia.
Objective: To explore and understand the barriers and facilitators for correctly using maintenance/controller and rescue treatments in adults with mild to moderate asthma (GINA 2020 classification) attending a reference center for asthma in Bogotá, Colombia, during the years 2021-2022.
Methods: A qualitative study with a phenomenological approach using semi-structured interviews with adults with mild to moderate asthma, under a purposive non-probabilistic sampling. Data analysis was conducted using Nvivo software (Version 11.
Comparing the effects of two low-dose budesonide suspension nebulization treatments on asthma among young children: a multicenter study.
J Asthma
August 2025
Department of Pediatrics, Ruijin Hospital Affiliated with Shanghai Jiaotong University School of Medicine, Shanghai, China.
Objective: To evaluate the effects of treatment with nebulized budesonide inhalation suspension (BIS) at dosages of 500 µg/day and 250 µg/day on mild to moderate asthma in young children.
Methods: This was a randomized, parallel group, open-label study at 19 Chinese clinical sites. A total of 340 patients (4-7 years) with mild to moderate persistent pediatric asthma were randomly and evenly divided into the 500-µg group (BIS 500 µg/day) and the 250-µg group (BIS 250 µg/day); 323 patients completed the study.